Extract
Long-term azithromycin treatment reduced exacerbations in adults with persistent symptomatic asthma in the AMAZES trial (Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235) [1]. However, response to treatment was variable between participants and the characteristics of those who experience most clinical benefit have not been determined. The inability to define a specific population who are more responsive limits the ability to personalise this therapy, which is the goal for airways disease management [2]. With recent studies identifying airway Haemophilus influenzae colonisation as a candidate marker for asthma subgrouping [3, 4], we assessed whether H. influenzae abundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations.
Abstract
Sputum Haemophilus influenzae load predicts response to azithromycin in adults with persistent uncontrolled asthma: secondary findings from the AMAZES trial https://bit.ly/3f3tJ71
Acknowlegement
The following investigators constitute the AMAZES Investigators Group: Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. Peters, Melissa Baraket and Guy B. Marks.
Footnotes
Conflict of interest: S.L. Taylor has nothing to disclose.
Conflict of interest: K.L. Ivey has nothing to disclose.
Conflict of interest: P.G. Gibson reports personal fees for lectures from AstraZeneca, GlaxoSmithKline and Novartis, grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.
Conflict of interest: J.L. Simpson has nothing to disclose.
Conflict of interest: G.B. Rogers has nothing to disclose.
Support statement: This work was supported by the National Health and Medical Research Council (NHMRC project identifier 569246). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 29, 2020.
- Accepted April 24, 2020.
- Copyright ©ERS 2020